Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2023; 11(35): 8300-8309
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8300
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8300
Efficacy of prednisone combined with mycophenolate mofetil for immunoglobulin A nephropathy with moderate-to-severe renal dysfunction
Mei-Juan Meng, Ling Hu, Yun Fan, Han Gao, Han-Zhi Chen, Cai-Mei Chen, Zhen Qi, Bin Liu, Department of Nephrology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, Jiangsu Province, China
Author contributions: Meng MJ, Hu L, and Fan Y contributed equally to this work and are co-first authors; Meng MJ contributed to methodology; Hu L contributed to data curation; Fan Y contributed to visualization; Gao H contributed to data curation; Chen HZ, Chen CM, and Qi Z contributed to resources and validation; Liu B contributed to funding acquisition; Meng MJ, Hu L, Fan Y, and Liu B contributed to conceptualization; Hu L and Fan Y contributed to investigation; Meng MJ, Hu L, and Fan Y contributed to writing-original draft, writing - review and editing; Meng MJ and Liu B contributed to project administration; Hu L and Liu B contributed to supervision.
Institutional review board statement: This study was approved by the Ethics Committee of Wuxi People's Hospital affiliated with Nanjing Medical University (approval no. KY23117).
Informed consent statement: Owing to the retrospective nature of the study, the requirement for written informed consent was waived.
Conflict-of-interest statement: All the authors declare no conflict of interest.
Data sharing statement: The data can be obtained from the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Liu, MM, Chief Physician, Department of Nephrology, Wuxi People's Hospital Affiliated to Nanjing Medical University, No. 299 Qingyang Road, Liangxi District, Wuxi 214023, Jiangsu Province, China. wuxi_liu@163.com
Received: November 3, 2023
Peer-review started: November 3, 2023
First decision: November 16, 2023
Revised: November 27, 2023
Accepted: November 30, 2023
Article in press: November 30, 2023
Published online: December 16, 2023
Processing time: 41 Days and 2.3 Hours
Peer-review started: November 3, 2023
First decision: November 16, 2023
Revised: November 27, 2023
Accepted: November 30, 2023
Article in press: November 30, 2023
Published online: December 16, 2023
Processing time: 41 Days and 2.3 Hours
Core Tip
Core Tip: In this study, the clinical and follow-up data of patients were retrospectively analyzed to explore the effectiveness and safety of prednisone combined with mycophenolate mofetil to guide the selection of clinical treatment of primary immunoglobulin A nephropathy (IgAN) with renal dysfunction. The results showed that mycophenolate ethyl ester combined with prednisone were more effective in treating patients with IgAN than prednisone alone, and could effectively improve renal function.